By co‐targeting CD70 and CD33, they aimed to address antigen heterogeneity in AML treatment and mitigate systemic toxicity in a preclinical model, while simultaneously redirecting untransduced bystander T cells to CD33‐positive tumour cells to enhance antitumour activity.94 The gene discussed is CD33; the disease is acute myeloid leukemia.